Publication | Closed Access

Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ETAreceptor antagonist

Pulmonary Vascular HypertensionHypertensionPulmonary Arterial HypertensionCardiovascular DiseaseSitaxsentan SodiumMedicineAntihypertensive TherapyPhysiologyVascular PharmacologyCardiovascular PharmacologyVascular BiologyPharmacotherapyActive Etareceptor AntagonistPublic HealthPharmacologyCardiologyPulmonary Vascular Disease